Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 18.278
Filter
1.
Can Vet J ; 65(7): 638-642, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38952756

ABSTRACT

An 11-year-old neutered male large crossbreed dog was presented for investigation because of a 10-day history of progressive lethargy, hyporexia, and pyrexia. Physical and dermatological examinations were unremarkable. Blood biochemical analysis identified a marked total and ionized hypercalcemia and increased C-reactive protein concentration. Bicavitary computed tomography screening for causes of the dog's clinical and biochemical abnormalities identified a diffuse panniculitis. Histopathological examination of full-thickness skin biopsies was consistent with pyogranulomatous inflammation. Extensive histochemical staining revealed no infectious etiology. Complete clinical and biochemical remissions were observed after starting immunosuppressive, followed by tapering, doses of prednisolone, supporting an immune-mediated etiology. Key clinical message: Sterile, immune-mediated pyogranulomatous inflammation should remain a differential diagnosis for hypercalcemia in dogs. Significant dermatological disease may occur without visible abnormalities.


Panniculite pyogranulomateuse à médiation immunitaire avec hypercalcémie chez un chienUn grand chien croisé mâle castré de 11 ans a été présenté pour examen en raison d'antécédents de léthargie progressive, d'hyporexie et de pyrexie depuis 10 jours. Les examens physiques et dermatologiques étaient sans particularité. L'analyse biochimique du sang présentait une hypercalcémie totale et ionisée marquée et une concentration accrue de protéine C-réactive. Le dépistage par tomodensitométrie bicavitaire des causes des anomalies cliniques et biochimiques du chien a identifié une panniculite diffuse. L'examen histopathologique des biopsies cutanées de pleine épaisseur était compatible avec une inflammation pyogranulomateuse. Un examen par coloration histochimique extensive n'a révélé aucune étiologie infectieuse. Les rémissions cliniques et biochimiques complètes ont été observées après le début du traitement immunosuppresseur, suivies d'une diminution progressive des doses de prednisolone, confirmant une étiologie à médiation immunitaire.Message clinique clé:L'inflammation pyogranulomateuse stérile à médiation immunitaire doit rester un diagnostic différentiel de l'hypercalcémie chez le chien. Une maladie dermatologique importante peut survenir sans anomalies visibles.(Traduit par Dr Serge Messier).


Subject(s)
Dog Diseases , Hypercalcemia , Panniculitis , Animals , Dogs , Dog Diseases/diagnosis , Dog Diseases/drug therapy , Dog Diseases/pathology , Male , Panniculitis/veterinary , Panniculitis/diagnosis , Hypercalcemia/veterinary , Prednisolone/therapeutic use , Immunosuppressive Agents/therapeutic use
2.
BMJ Case Rep ; 17(6)2024 Jun 25.
Article in English | MEDLINE | ID: mdl-38925673

ABSTRACT

A white Caucasian woman in her 30s presented with an indurated lesion on her right upper arm. Panniculitis was clinically suspected. Antinuclear antibody testing was positive but incisional biopsy showed subcutaneous panniculitis-like T-cell lymphoma (SPTCL), although with some unusual features more in keeping with lupus. Initial treatment was with oral prednisolone and radiotherapy but with only partial response. A second biopsy was taken from an area of presumed residual disease. This displayed histological features that were much more typical of lupus erythematosus profundus (LEP) but with tiny foci suggesting concomitant microscopic areas of SPTCL. Immunofluorescence for IgM was positive. This case highlights the rare occurrence of a patient with overlapping clinical and pathological features of SCPTL and LEP. It emphasises the need for close clinicopathological correlation in the workup of patients with suspected panniculitis and the importance of careful pathological examination for features of both diseases.


Subject(s)
Lymphoma, T-Cell , Panniculitis, Lupus Erythematosus , Panniculitis , Humans , Female , Panniculitis/diagnosis , Panniculitis/pathology , Panniculitis, Lupus Erythematosus/diagnosis , Panniculitis, Lupus Erythematosus/drug therapy , Panniculitis, Lupus Erythematosus/pathology , Lymphoma, T-Cell/diagnosis , Lymphoma, T-Cell/pathology , Adult , Diagnosis, Differential , Biopsy , Prednisolone/therapeutic use
3.
BMC Pediatr ; 24(1): 414, 2024 Jun 26.
Article in English | MEDLINE | ID: mdl-38926645

ABSTRACT

BACKGROUND: Guillain‒Barre syndrome (GBS) is an acute inflammatory peripheral neuropathy caused by autoimmunity. Gangliosides and sulfatides are important components of peripheral nerves. Anti-sulfatide antibody-mediated complement is associated with acute sensorimotor peripheral neuropathy in GBS, which is characterized by pain and paresthesias. CASE PRESENTATION: The child was a 7-year-old girl with headache and abdominal pain, followed by limb numbness and pain. Cranial imaging showed ventricular dilatation, peripheral nerve function conduction examination showed polyradiculopathy, and cerebrospinal fluid tests showed normal cell counts but elevated protein levels, all of which led to the diagnosis of GBS. After treatment with intravenous immunoglobulin (400 mg/kg × 5 days), the symptoms did not improve, and muscle strength progressively worsened, accompanied by paroxysmal complexion flushing, heart rate fluctuation, hyperhidrosis, and a progressive increase in cerebrospinal fluid protein (up to 3780.1 mg/L). On the basis of these findings combined with serum anti-sulfatide IgM positivity, anti-sulfatide antibody-related GBS was considered, and treatment with low-dose prednisolone (1 mg/kg/d) led to symptom improvement. CONCLUSIONS: Anti-sulfatide antibody-associated GBS is associated with small fiber peripheral neuropathy. The main manifestations are pain, paresthesias and autonomic dysfunction. In addition to the dysfunction of spinal nerve root absorption caused by increased cerebrospinal fluid protein, autonomic dysfunction may be involved in pain. When the therapeutic effect of immunoglobulin is not satisfactory, a low dose and short course of corticosteroids can be considered, and the prognosis is good.


Subject(s)
Abdominal Pain , Guillain-Barre Syndrome , Headache , Sulfoglycosphingolipids , Humans , Female , Child , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/drug therapy , Abdominal Pain/etiology , Headache/etiology , Headache/drug therapy , Sulfoglycosphingolipids/immunology , Autoantibodies/blood , Prednisolone/therapeutic use
4.
BMC Geriatr ; 24(1): 522, 2024 Jun 16.
Article in English | MEDLINE | ID: mdl-38880897

ABSTRACT

BACKGROUND: IgG4-related diseases are very uncommon, and its diagnosis and treatment are complicated as it encompasses multiple disciplines. CASE PRESENTATION: A 77-year-old woman was admitted with a jaw mass and nausea and vomiting. Laboratory tests showed elevated serum IgG4, pituitary MRI suggested thickening of the pituitary stalk, and head and neck CT suggested orbital and mandibular masses. Patients with mandibular mass were diagnosed with Mikulicz's disease with IgG4-related hypophysitis. We found no other evidence of causing thickening of the pituitary stalk. She was given oral prednisolone 30 mg daily, and her nausea and vomiting improved significantly, and the mandibular and ocular masses decreased in size. CONCLUSION: Mikulicz's disease combined with IgG4-related hypophysitis is a rare case of IgG4-RD in elderly women. IgG4-RD is one of the causes of head and neck exocrine gland mass and pituitary stalk thickening in the elderly.


Subject(s)
Autoimmune Hypophysitis , Immunoglobulin G4-Related Disease , Mikulicz' Disease , Humans , Aged , Female , Mikulicz' Disease/drug therapy , Mikulicz' Disease/complications , Mikulicz' Disease/diagnosis , Immunoglobulin G4-Related Disease/complications , Immunoglobulin G4-Related Disease/drug therapy , Immunoglobulin G4-Related Disease/diagnosis , Autoimmune Hypophysitis/complications , Autoimmune Hypophysitis/drug therapy , Immunoglobulin G/blood , Prednisolone/therapeutic use , Prednisolone/administration & dosage , Magnetic Resonance Imaging/methods
5.
BMJ Case Rep ; 17(6)2024 Jun 17.
Article in English | MEDLINE | ID: mdl-38885997

ABSTRACT

Rheumatoid pleurisy is common in patients with rheumatoid arthritis, but distinguishing it from other diseases, such as heart failure and tuberculous pleurisy, is often difficult. A man in his 70s with stable rheumatoid arthritis presented with cardiac enlargement and bilateral pleural effusion on chest radiography. Pleural fluid studies showed lymphocytosis, adenosine deaminase level of 51.6 U/L and rheumatoid factor level of 2245.3 IU/mL, suggestive of rheumatoid pleurisy and tuberculous pleurisy. Thoracoscopy under local anaesthesia revealed erythema of the parietal pleura, small papillary projections and fibrin deposits. H&E-stained biopsy specimens showed inflammatory granulomas with strong lymphocytic infiltration and non-caseating granulomas. He was diagnosed with rheumatoid pleurisy. His symptoms improved with 30 mg of prednisolone. This study highlights that biopsy using thoracoscopy under local anaesthesia effectively diagnoses rheumatoid pleurisy, which may be challenging to diagnose.


Subject(s)
Anesthesia, Local , Pleurisy , Thoracoscopy , Humans , Male , Thoracoscopy/methods , Pleurisy/diagnosis , Pleurisy/pathology , Aged , Biopsy/methods , Thoracic Wall/pathology , Diagnosis, Differential , Arthritis, Rheumatoid , Prednisolone/therapeutic use , Prednisolone/administration & dosage , Pleura/pathology , Pleura/diagnostic imaging
6.
Clin Drug Investig ; 44(6): 425-437, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38869717

ABSTRACT

BACKGROUND AND OBJECTIVE: Intravenous immunoglobulin (IVIG) is a prominent therapeutic agent for Kawasaki disease (KD) that significantly reduces the incidence of coronary artery anomalies. Various methodologies, including machine learning, have been employed to develop IVIG non-responder prediction models; however, their validation and reproducibility remain unverified. This study aimed to develop a predictive scoring system for identifying IVIG nonresponders and rigorously test the accuracy and reliability of this system. METHODS: The study included an exposure group of 228 IVIG non-responders and a control group of 997 IVIG responders. Subsequently, a predictive machine learning model was constructed. The Shizuoka score, including variables such as the "initial treatment date" (cutoff: < 4 days), sodium level (cutoff: < 133 mEq/L), total bilirubin level (cutoff: ≥ 0.5 mg/dL), and neutrophil-to-lymphocyte ratio (cutoff: ≥ 2.6), was established. Patients meeting two or more of these criteria were grouped as high-risk IVIG non-responders. Using the Shizuoka score to stratify IVIG responders, propensity score matching was used to analyze 85 patients each for IVIG and IVIG-added prednisolone treatment in the high-risk group. In the IVIG plus prednisolone group, the IVIG non-responder count significantly decreased (p < 0.001), with an odds ratio of 0.192 (95% confidence interval 0.078-0.441). CONCLUSIONS: Intravenous immunoglobulin non-responders were predicted using machine learning models and validated using propensity score matching. The initiation of initial IVIG-added prednisolone treatment in the high-risk group identified by the Shizuoka score, crafted using machine learning models, appears useful for predicting IVIG non-responders.


Subject(s)
Immunoglobulins, Intravenous , Machine Learning , Mucocutaneous Lymph Node Syndrome , Mucocutaneous Lymph Node Syndrome/drug therapy , Mucocutaneous Lymph Node Syndrome/diagnosis , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/therapeutic use , Male , Female , Child, Preschool , Infant , Prednisolone/therapeutic use , Prednisolone/administration & dosage , Child , Retrospective Studies
7.
J Assoc Physicians India ; 72(6): 15-19, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38881128

ABSTRACT

BACKGROUND: The modified Ponticelli regimen (mPR) is a first-line therapy in patients with idiopathic membranous nephropathy (IMN); however, it has a less favorable safety profile. Though mycophenolate mofetil (MMF) + steroid (S) is not recommended by Kidney Disease Improving Global Outcomes guidelines, it can be used as an alternative to mPR due to higher tolerability and steroid-sparing effect. Thus, we compared the safety and effectiveness of MMF + S and mPR regimens in patients with IMN. METHODS: This randomized, open-label study enrolled patients with adult-onset nephrotic syndrome (NS) and biopsy-proven IMN. Forty-two patients were allocated to MMF + S group (MMF 1 gm twice daily + oral prednisolone 0.5 mg/kg/day; n = 21) and mPR group [methylprednisolone (1 gm intravenous) for 3 days followed by alternating monthly cycles of oral prednisolone (0.5 mg/kg/day) for the next 27 days and cyclophosphamide (2 mg/kg/day) for 6 months; n = 21]. The primary outcome measure was change in urinary protein creatinine ratio (UPCR). RESULTS: At 6 months, both groups demonstrated a significant increase in serum albumin levels and estimated glomerular filtration rate (eGFR) (both p-values <0.0001) as well as a decrease in 24-hour proteinuria (MMF + S group: p-value = 0.003, and mPR group: p-value <0.0001) and UPCR (both p-values <0.0001). However, the groups did not differ in any of these parameters at any of the monthly follow-up visits. Moreover, the groups did not differ significantly in terms of the composite remission rates (61.91% for MMF + S group and 71.43% for mPR group). CONCLUSION: MMF + S and mPR had comparable tolerability and effectiveness, with MMF-associated advantage of reduced steroid exposure.


Subject(s)
Drug Therapy, Combination , Glomerulonephritis, Membranous , Immunosuppressive Agents , Mycophenolic Acid , Prednisolone , Humans , Glomerulonephritis, Membranous/drug therapy , Mycophenolic Acid/therapeutic use , Mycophenolic Acid/administration & dosage , Male , Female , Adult , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Prednisolone/administration & dosage , Prednisolone/therapeutic use , Middle Aged , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Cyclophosphamide/therapeutic use , Cyclophosphamide/administration & dosage , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Treatment Outcome
8.
J Med Case Rep ; 18(1): 268, 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38835063

ABSTRACT

BACKGROUND: Immunoglobulin G4-related disease is marked by extensive inflammation and fibrosis of an unknown autoimmune component, with an overall incidence ranging from 0.78 to 1.39 per 105 person-years. Sinonasal immunoglobulin G4-related disease is atypical and exceedingly uncommon in the existing literature, frequently manifesting clinically as chronic rhinosinusitis, epistaxis, and facial pain. CASE PRESENTATION: This report describes a 25-year-old Iraqi female who has been suffering from symptoms of chronic rhinosinusitis for 8 years. Despite undergoing several surgeries, there has been no improvement in her symptoms. A tissue biopsy that revealed dense lymphoplasmocytosis with noticeable plasma cell infiltration, storiform fibrosis, and obliterative angitis, along with positive immunohistochemical staining for Immunoglobulin G4 plasma cells, finally confirmed the diagnosis of sinonasal immunoglobulin G4-related disease. The patient responded well to oral prednisolone and methotrexate treatments. CONCLUSIONS: The main objective of the current report is to raise awareness among physicians about the significance of promptly identifying and diagnosing this rarity, thus preventing the adverse consequences linked to delayed diagnosis and treatment initiation.


Subject(s)
Immunoglobulin G4-Related Disease , Prednisolone , Sinusitis , Humans , Female , Immunoglobulin G4-Related Disease/diagnosis , Immunoglobulin G4-Related Disease/drug therapy , Immunoglobulin G4-Related Disease/complications , Adult , Sinusitis/drug therapy , Sinusitis/immunology , Sinusitis/diagnosis , Prednisolone/therapeutic use , Rhinitis/diagnosis , Rhinitis/drug therapy , Rhinitis/immunology , Methotrexate/therapeutic use , Chronic Disease , Biopsy , Treatment Outcome
9.
BMC Nephrol ; 25(1): 198, 2024 Jun 18.
Article in English | MEDLINE | ID: mdl-38890580

ABSTRACT

BACKGROUND: Sarcoidosis is a systemic disease that can affect multiple organs. While pulmonary sarcoidosis is most commonly observed, renal sarcoidosis occurs less frequently. We herein report a case of sarcoidosis with an exceptionally rare distribution including renal lesions. CASE PRESENTATION: A 51-year-old Japanese female was referred because of bilateral parotid swelling and renal dysfunction. Computed tomography scan showed the swelling of bilateral kidneys, parotid glands, and uterus. Ga scintigraphy also showed remarkable accumulation in these organs. Renal biopsy and cytological evaluations of parotid gland and uterus were performed and she was diagnosed as sarcoidosis of these organs. Treatment was initiated with prednisolone 40 mg/day and then renal dysfunction subsequently improved. In addition, the swelling of parotid glands and uterus improved and Ga accumulation in each organ had disappeared. CONCLUSION: This is a first case of renal sarcoidosis complicated by parotid glands and uterus lesions. Pathological findings and the reactivity observed in Ga scintigraphy indicated the presence of lesions in these organs.


Subject(s)
Kidney Diseases , Sarcoidosis , Humans , Female , Middle Aged , Sarcoidosis/complications , Sarcoidosis/diagnostic imaging , Sarcoidosis/drug therapy , Kidney Diseases/diagnostic imaging , Kidney Diseases/pathology , Kidney Diseases/complications , Kidney Diseases/etiology , Parotid Gland/pathology , Parotid Gland/diagnostic imaging , Uterine Diseases/complications , Uterine Diseases/pathology , Uterine Diseases/diagnostic imaging , Prednisolone/therapeutic use , Parotid Diseases/diagnostic imaging , Parotid Diseases/etiology , Parotid Diseases/pathology , Radionuclide Imaging , Tomography, X-Ray Computed
10.
BMJ Case Rep ; 17(6)2024 Jun 05.
Article in English | MEDLINE | ID: mdl-38839406

ABSTRACT

Steroid-induced acute pancreatitis is a rare form of pancreatitis that requires intensive care and has a high morbidity and mortality rate as there is no specific treatment. Management of steroid-induced pancreatitis is generally non-specific and supportive. Here, we are presenting a man in his 40s presented with epigastric pain, fever and vomiting. The patient was diagnosed case of rheumatoid arthritis, for which he was receiving regular 5 mg oral prednisolone therapy. Based on history, and clinical, biochemical and radiological imaging a diagnosis of steroid-induced pancreatitis was made, which was successfully managed with the help of ulinastatin and other supportive treatments. A serine protease inhibitor like ulinastatin may be used early in the clinical management of steroid-induced pancreatitis.


Subject(s)
Glycoproteins , Pancreatitis , Prednisolone , Trypsin Inhibitors , Humans , Male , Prednisolone/therapeutic use , Pancreatitis/chemically induced , Pancreatitis/drug therapy , Adult , Trypsin Inhibitors/therapeutic use , Arthritis, Rheumatoid/drug therapy , Glucocorticoids/therapeutic use , Glucocorticoids/adverse effects
11.
J Clin Neurosci ; 124: 142-143, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38705026

ABSTRACT

Corticosteroids are a potential treatment to combat Complex Regional Pain Syndrome, however the adverse effect profile far outweighs the benefits of using them. Avascular necrosis and Osteonecrosis are among well defined adverse effects. Postmenopausal women are especially affected by corticosteroids due to loss of estrogen. Diabetics are an interesting study as their pain perception is altered due to either high cortisol levels or the development of peripheral neuropathy.


Subject(s)
Prednisolone , Reflex Sympathetic Dystrophy , Humans , Reflex Sympathetic Dystrophy/drug therapy , Prednisolone/therapeutic use , Prednisolone/administration & dosage , Female
12.
Neuromuscul Disord ; 39: 37-41, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38772072

ABSTRACT

The effect of treatment with efgartigimod in seronegative myasthenia gravis (MG) remains unclear. This retrospective study aimed to evaluate symptomatic changes and safety of treatment with efgartigimod in patients with generalized MG (gMG) double-seronegative for acetylcholine receptor antibody and muscle-specific kinase antibody. We reviewed the medical records of double-seronegative gMG treated with 10 mg/kg efgartigimod once/week per cycle (4 weeks) from June 2022 to June 2023. A total of 16 patients were included. MG-activities of daily living (ADL) scores improved from 9.2 to 7.4. Mean prednisolone dose was reduced from 5.4 to 4.1 mg/day. The duration before MG-ADL deterioration after the end of a cycle was 6.1 weeks. Five patients had mild adverse events. This retrospective study revealed no significant treatment benefit in the outcomes of patients with double-seronegative gMG treated with efgartigimod.


Subject(s)
Myasthenia Gravis , Humans , Myasthenia Gravis/drug therapy , Retrospective Studies , Male , Female , Middle Aged , Adult , Aged , Treatment Outcome , Activities of Daily Living , Receptors, Cholinergic/immunology , Autoantibodies/blood , Prednisolone/therapeutic use
13.
BMJ Case Rep ; 17(5)2024 May 08.
Article in English | MEDLINE | ID: mdl-38719253

ABSTRACT

The combination therapy of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors is approved for treating patients with BRAF V600E-positive tumours, including melanoma and lung cancer. Several case reports indicated autoimmune side effects associated with the use of BRAF and MEK inhibitors. Still, the effects of these drugs on the immune system were not fully elucidated. Here, we report a patient with large-vessel vasculitis diagnosed after initiation of treatment with dabrafenib and trametinib for BRAF V600E-positive metastatic lung adenocarcinoma. She was a never-smoker woman in her early 70s who presented with a chronic cough and was diagnosed with BRAF V600E-positive metastatic lung adenocarcinoma by transbronchial lung biopsy. She was successfully treated with prednisolone and methotrexate while BRAF and MEK inhibitors were continued. We should be careful about autoimmune diseases using BRAF and MEK inhibitors.


Subject(s)
Adenocarcinoma of Lung , Imidazoles , Lung Neoplasms , Oximes , Protein Kinase Inhibitors , Proto-Oncogene Proteins B-raf , Pyridones , Pyrimidinones , Vasculitis , Humans , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Female , Pyridones/adverse effects , Pyridones/therapeutic use , Pyrimidinones/therapeutic use , Pyrimidinones/adverse effects , Lung Neoplasms/drug therapy , Aged , Adenocarcinoma of Lung/drug therapy , Imidazoles/adverse effects , Imidazoles/therapeutic use , Oximes/adverse effects , Oximes/therapeutic use , Vasculitis/chemically induced , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/therapeutic use , Prednisolone/therapeutic use , Methotrexate/therapeutic use , Methotrexate/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
14.
Med J Malaysia ; 79(3): 296-305, 2024 May.
Article in English | MEDLINE | ID: mdl-38817062

ABSTRACT

INTRODUCTION: The efficacy of long-course corticosteroid therapy in treating COVID-19-related diffuse interstitial lung abnormalities (DILA) needs to be better understood. We aimed to investigate the benefits of 12-week corticosteroid treatment in COVID-19-related DILA by evaluating computed tomography (CT) lung severity scores. MATERIALS AND METHODS: This retrospective, single-centre observational study included patients aged 18 years or older admitted with moderate to severe COVID-19 pneumonia who received 12 weeks of oral prednisolone between January 2021 and December 2021. We recorded clinical parameters, baseline CT scores and post-treatment, modified Medical Research Council (mMRC) dyspnoea scale and pulmonary function tests. RESULTS: A total of 330 patients were analysed. The mean (standard deviation, SD) age was 54.6 (14.2) years, and 43% were females. Three-point nine per cent (3.9%) require noninvasive ventilation (NIV), while 14.6% require mechanical ventilation (MV). On follow-up at 12 weeks, the CT patterns showed improvement in ground-glass opacities, perilobular density and consolidation. There was an improvement in the mean (SD) CT score before and after prednisolone therapy, with values of 17.3 (5.3) and 8.6 (5.5), respectively (p<0.001). The median mMRC was 1 (IQR 0-1), and 98.8% had a radiological response. The common side effects of prednisolone therapy were weight gain (13.9%), hyperglycaemia (1.8%) and cushingoid habitus (0.6%). CONCLUSION: A 12-week treatment with prednisolone showed significant improvement in CT scores with minimal residual dyspnoea and was relatively safe. Longer duration of steroids may be beneficial in moderate to severe COVID-19- related DILA.


Subject(s)
COVID-19 , Lung Diseases, Interstitial , Prednisolone , Tomography, X-Ray Computed , Humans , Female , Male , Middle Aged , Retrospective Studies , COVID-19/complications , Adult , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/etiology , Aged , Prednisolone/administration & dosage , Prednisolone/therapeutic use , Treatment Outcome , COVID-19 Drug Treatment , SARS-CoV-2 , Adrenal Cortex Hormones/therapeutic use , Adrenal Cortex Hormones/administration & dosage , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Severity of Illness Index
15.
Vet Dermatol ; 35(4): 432-436, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38695235

ABSTRACT

Auricular chondritis of unknown cause was suspected in a 10-year-old male Bolognese dog with a five-month history of painful bilateral nodular and ulcerative pyogranulomatous dermatitis of the pinnae with putative auricular cartilage destruction. Pain and lesions resolved with immunosuppressive doses of prednisolone, yet the condition resulted in deformity of both pinnae and external canals.


Une chondrite auriculaire d'étiologie inconnue est suspectée chez un bichon bolonais mâle de 10 ans qui présente depuis 5 mois une dermatite pyogranulomateuse nodulaire et ulcéreuse bilatérale douloureuse du pavillon de l'oreille avec une destruction présumée du cartilage auriculaire. La douleur et les lésions disparaissent avec des doses immunosuppressives de prednisolone, mais l'affection entraîne une déformation des deux pavillons et des conduits auriculaires externes.


Suspeitou­se de condrite auricular de causa desconhecida em um cão macho Bolonhês de 10 anos de idade com um histórico de cinco meses de dermatite piogranulomatosa ulcerativa e nodular bilateral no pavilhão auricular com suposta destruição de cartilagem auricular. A dor e as lesões resolveram com doses imunossupressoras de prednisolona apesar de a etiologia ter resultado na deformidade de ambas as orelhas e condutos auditivos.


Se sospechó la existencia de una condritis auricular de causa desconocida en un perro boloñés de 10 años con historia de 5 meses de duración de una dermatitis nodular ulcerativa piogramulomatosa y bilateral en las orejas con posible destrucción del cartílago auricular. El dolor y las lesiones se resolvieron con dosis inmunosupresoras de prednisolona pero la enfermedad produjo deformación de ambas orejas y de los canales auriculares externos.


Subject(s)
Dog Diseases , Otitis Externa , Animals , Dogs , Male , Dog Diseases/pathology , Dog Diseases/drug therapy , Dog Diseases/diagnosis , Otitis Externa/veterinary , Otitis Externa/pathology , Otitis Externa/drug therapy , Otitis Externa/microbiology , Cartilage Diseases/veterinary , Cartilage Diseases/pathology , Cartilage Diseases/drug therapy , Ear Cartilage/pathology , Prednisolone/therapeutic use , Prednisolone/administration & dosage , Ear Auricle/pathology
16.
Microsc Microanal ; 30(3): 539-551, 2024 Jul 04.
Article in English | MEDLINE | ID: mdl-38758132

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown origin with limited treatment options and poor prognosis. The encouraging findings from preclinical investigations utilizing mesenchymal stem cells (MSCs) indicated that they could serve as a promising therapeutic alternative for managing chronic lung conditions, such as IPF. The objective of this study was to compare the efficiency of bone marrow-derived MSCs (BM-MSCs) versus prednisolone, the standard anti-inflammatory medication, in rats with bleomycin (BLM)-induced lung fibrosis. Four groups were created: a control group, a BLM group, a prednisolone-treated group, and a BM-MSCs-treated group. To induce lung fibrosis, 5 mg/kg of BLM was administered intratracheally. BLM significantly increased serum levels of pro-inflammatory cytokines and oxidative stress markers. The disturbed lung structure was also revealed by light and transmission electron microscopic studies. Upregulation in the immune expression of alpha-smooth muscle actin, transforming growth factor beta-1, and Bax was demonstrated. Interestingly, all findings significantly regressed on treatment with prednisolone and BM-MSCs. However, treatment with BM-MSCs showed better results than with prednisolone. In conclusion, BM-MSCs could be a promising approach for managing lung fibrosis.


Subject(s)
Bleomycin , Disease Models, Animal , Mesenchymal Stem Cells , Prednisolone , Pulmonary Fibrosis , Animals , Prednisolone/therapeutic use , Prednisolone/pharmacology , Rats , Pulmonary Fibrosis/therapy , Pulmonary Fibrosis/pathology , Lung/pathology , Immunohistochemistry , Male , Cytokines/metabolism , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Mesenchymal Stem Cell Transplantation/methods , Histocytochemistry , Bone Marrow Cells , Microscopy, Electron, Transmission
17.
Adv Rheumatol ; 64(1): 38, 2024 05 08.
Article in English | MEDLINE | ID: mdl-38720354

ABSTRACT

BACKGROUND: This study examines the association of standard-of-care systemic lupus erythematosus (SLE) medications with key outcomes such as low disease activity attainment, flares, damage accrual, and steroid-sparing, for which there is current paucity of data. METHODS: The Asia Pacific Lupus Collaboration (APLC) prospectively collects data across numerous sites regarding demographic and disease characteristics, medication use, and lupus outcomes. Using propensity score methods and panel logistic regression models, we determined the association between lupus medications and outcomes. RESULTS: Among 1707 patients followed over 12,689 visits for a median of 2.19 years, 1332 (78.03%) patients achieved the Lupus Low Disease Activity State (LLDAS), 976 (57.18%) experienced flares, and on most visits patients were taking an anti-malarial (69.86%) or immunosuppressive drug (76.37%). Prednisolone, hydroxychloroquine and azathioprine were utilised with similar frequency across all organ domains; methotrexate for musculoskeletal activity. There were differences in medication utilisation between countries, with hydroxychloroquine less frequently, and calcineurin inhibitors more frequently, used in Japan. More patients taking leflunomide, methotrexate, chloroquine/hydroxychloroquine, azathioprine, and mycophenolate mofetil/mycophenolic acid were taking ≤ 7.5 mg/day of prednisolone (compared to > 7.5 mg/day) suggesting a steroid-sparing effect. Patients taking tacrolimus were more likely (Odds Ratio [95% Confidence Interval] 13.58 [2.23-82.78], p = 0.005) to attain LLDAS. Patients taking azathioprine (OR 0.67 [0.53-0.86], p = 0.001) and methotrexate (OR 0.68 [0.47-0.98], p = 0.038) were less likely to attain LLDAS. Patients taking mycophenolate mofetil were less likely to experience a flare (OR 0.79 [0.64-0.97], p = 0.025). None of the drugs was associated with a reduction in damage accrual. CONCLUSIONS: This study suggests a steroid-sparing benefit for most commonly used standard of care immunosuppressants used in SLE treatment, some of which were associated with an increased likelihood of attaining LLDAS, or reduced incidence of flares. It also highlights the unmet need for effective treatments in lupus.


Subject(s)
Antimalarials , Azathioprine , Glucocorticoids , Hydroxychloroquine , Immunosuppressive Agents , Lupus Erythematosus, Systemic , Methotrexate , Prednisolone , Standard of Care , Humans , Lupus Erythematosus, Systemic/drug therapy , Female , Immunosuppressive Agents/therapeutic use , Hydroxychloroquine/therapeutic use , Male , Glucocorticoids/therapeutic use , Adult , Azathioprine/therapeutic use , Prednisolone/therapeutic use , Methotrexate/therapeutic use , Antimalarials/therapeutic use , Cohort Studies , Middle Aged , Mycophenolic Acid/therapeutic use , Leflunomide/therapeutic use , Calcineurin Inhibitors/therapeutic use , Logistic Models , Propensity Score , Severity of Illness Index , Tacrolimus/therapeutic use , Symptom Flare Up , Treatment Outcome , Antirheumatic Agents/therapeutic use
18.
BMJ Case Rep ; 17(5)2024 May 08.
Article in English | MEDLINE | ID: mdl-38719258

ABSTRACT

A gentleman in his 90s presented with a slowly enlarging goitre over 18 months, causing manifestations of superior vena cava obstruction, dysphagia and hoarseness of voice. Investigations were suggestive of a fibrosing thyroid pathology. Surgical management was avoided due to high surgical risk. Treatment included prednisolone and tamoxifen with palliative management in the event of further medical deterioration. This article illustrates the difficulties in diagnosing and managing fibrosing thyroid diseases.


Subject(s)
Fibrosis , Hashimoto Disease , Thyroiditis , Humans , Male , Hashimoto Disease/complications , Hashimoto Disease/diagnosis , Hashimoto Disease/drug therapy , Thyroiditis/complications , Thyroiditis/drug therapy , Thyroiditis/diagnosis , Aged, 80 and over , Prednisolone/therapeutic use , Tamoxifen/therapeutic use , Diagnosis, Differential , Goiter/complications , Goiter/diagnosis , Thyroid Gland/pathology
19.
J Int Med Res ; 52(5): 3000605241248884, 2024 May.
Article in English | MEDLINE | ID: mdl-38713457

ABSTRACT

Kikuchi-Fujimoto disease (KFD), also known as histiocytic necrotizing lymphadenitis, is a rare, benign condition affecting young Oriental-Asian females. It is characterized by fever and tender cervical lymphadenopathy with an unclear aetiology, and in most longitudinal reviews, KFD occurs before systemic lupus erythematosus (SLE). Herein, the case of a 28-year-old Kuwaiti female without any relevant past medical history, who was simultaneously diagnosed with KFD and SLE following an Ebstein-Barr virus infection, is reported. The patient was treated with oral prednisolone, hydroxychloroquine, cyclosporin, and belimumab and her response was clinically and biochemically favourable. Although KFD is prevalent in Asian populations, it may affect all races. Early diagnosis of KFD is difficult, particularly when simultaneously diagnosed with SLE, but crucial to preventing inappropriate therapy. Clinicians need to know about this rare disease, especially when patients present with fever and swollen lymph nodes, due to a risk of misdiagnosis with tuberculosis or lymphoma, as these are more often thought to be the cause of such symptoms.


Subject(s)
Histiocytic Necrotizing Lymphadenitis , Lupus Erythematosus, Systemic , Humans , Histiocytic Necrotizing Lymphadenitis/diagnosis , Histiocytic Necrotizing Lymphadenitis/drug therapy , Histiocytic Necrotizing Lymphadenitis/pathology , Female , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Adult , Arabs , Prednisolone/therapeutic use , Prednisolone/administration & dosage
20.
BMJ Case Rep ; 17(5)2024 May 15.
Article in English | MEDLINE | ID: mdl-38749521

ABSTRACT

A woman in her 70s presented with anasarca and exertional dyspnoea. Investigation showed severe hypoalbuminaemia with no urinary or gastrointestinal protein losses. CT thorax reported lung consolidations, and transbronchial lung biopsy demonstrated organising pneumonia. Autoimmune myositis serology was positive for anti-Jo-1, anti-Ro-52, and anti-PM/Scl-100 antibodies. She was diagnosed with anti-synthetase syndrome with organising pneumonia. She was treated with oral prednisolone and oral mycophenolate mofetil with a good clinical response.


Subject(s)
Edema , Myositis , Humans , Female , Myositis/drug therapy , Myositis/diagnosis , Myositis/complications , Myositis/immunology , Aged , Edema/drug therapy , Edema/etiology , Prednisolone/therapeutic use , Prednisolone/administration & dosage , Mycophenolic Acid/therapeutic use , Tomography, X-Ray Computed , Pneumonia/drug therapy , Pneumonia/diagnosis , Dyspnea/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...